Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating satralizumab for efficacy, safety, pharmacokinetics, and pharmacodynamics in MOGAD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING